Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) — which skyrocketed 3,565% in 2019 thanks to a steady stream of positive clinical updates — were tanking Monday.

Why Axsome Shares Are Pulling Back After A Clinical Readout

Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and overall (key secondary endpoints, p=0.02, 0.035, and 0.031)

Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications

There are tangible near-term risks to the business in the face of the coronavirus pandemic, but investors with a long-term mindset could find this pharma stock attractive.

Here's Why The Best Is Yet to Come for Axsome Therapeutics

Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.

Axsome Expedites Completion Timeline of AD Study on AXS-05

Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Axsome Therapeutics (AXSM) Stock?

Axsome Therapeutics is wrapping up a late-stage clinical trial early to ensure patient safety during the coronavirus pandemic.

Alzheimer's Disease Drug Trial Concludes Early Due to COVID-19 Concerns

Randomizations concluded and trial participation in process of concluding to ensure patient safety during COVID-19 pandemic

Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q4 2019 Results - Earnings Call Transcript

The development-stage pharmaceutical company gave up a little ground, but important updates are right around the corner.

Here's Why Axsome Therapeutics Fell 10.2% in February

NEW YORK, March  05, 2020  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of Mark Jacobson as Chief Operating Officer. In this new role, Mr. Jacobson will oversee the day-to-day operations of the company, including aspects of research and development, manufacturing, program management, and corporate development.

Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer

On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

What's in Store for Axsome (AXSM) This Earnings Season?

Southwestern Energy

Virtus Investment Partners

These are the small cap stocks with the best value, fastest growth, and most momentum for March.

Top Small Cap Stocks for March 2020

NEW YORK, Feb.  20, 2020  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the INTERCEPT study, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the early treatment of migraine with AXS-07. AXS-07 (MoSEIC™ meloxicam/rizatriptan) is a novel, oral, investigational medicine with distinct dual mechanisms of action for the acute treatment of migraine. Axsome remains on track to report topline results from INTERCEPT in the first quarter of 2020.

Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine

Axsome: Catalysts Stacking

Axsome Therapeutics: There Still Remains A Lot Of Upside Potential For 2020

Axsome Therapeutics (AXSM) closed at $87.60 in the latest trading session, marking a +0.72% move from the prior day.

Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should Know

Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.

Axsome (AXSM) Completes Patient Randomization in TRD Study

NEW YORK, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient randomization in the STRIDE-1 study, a Phase 3, randomized, double-blind, active-controlled trial of AXS-05 in patients with treatment resistant depression (TRD). AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. Axsome remains on track to report topline results from STRIDE-1 in the first quarter of 2020.

Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

Axsome Had A Monumental Run, But Its Long-Term Potential Has Only Begun

Seagen

Vertex Pharmaceuticals

Shares of these biotech companies are near their five-year highs after some strong performances in 2019.

Are Biotech Stocks Due for a Correction in 2020?

Incyte

Two pharma stocks, one riding a wave of enthusiasm and one getting unfairly punished, look appealing from a long-term standpoint.

2 Top Growth Stocks to Buy in January

Galapagos

Lexicon Pharmaceuticals

These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q1 2020.

Top Biotech Stocks for Q1 2020

Cannae Hlds

These are the small cap stocks with the best value, fastest growth, and most momentum for January.

Top Small Cap Stocks for January 2020

The stock had an amazing run in 2019, with a 3,578% gain. What will happen in 2020?

News for Axsome Therapeutics Stock (AXSM)